Seoul (1)

Advanced, Refractory Cancer (1)

Active, not recruiting (1)

phase 2 (1)

Samsung Medical Center (1)

imatinib (1)

drug (1)

Other (1)

Interventional (1)

advanced, refractory cancer

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Active, not recruiting

Jun 13, 2022